Achieve CEO, Rick Stewart, will be presenting at the Barclays 27th Annual Global Healthcare Conference. Join in person or tune into the live webcast to learn more about our ambition to help people struggling with nicotine dependence.? ? When: Wednesday, March 12, 2025 @ 11:30am ET? Where: bit.ly/Achieve-Barclays?
Achieve Life Sciences
生物技术
Bothell,Washington 1,640 位关注者
Committed to the development of cytisinicline as the first new Rx treatment for nicotine dependence in ~20 years.
关于我们
Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
- 网站
-
https://achievelifesciences.com/
Achieve Life Sciences的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Bothell,Washington
- 类型
- 上市公司
- 创立
- 2015
- 领域
- Smoking Cessation、Biotechnology 和Pharmaceuticals
地点
-
主要
22722 29th Dr SE
Suite 100
US,Washington,Bothell,98021
Achieve Life Sciences员工
动态
-
Today, we will discuss our 4Q and full year 2024 performance and share an overview of key milestones behind Achieve Life Science’s progress towards an NDA submission. Tune into the webcast at 8:30am EDT today, Tuesday, March 11, 2025: https://lnkd.in/eRj3cqws? ? ICYMI: A webcast replay will be available approximately three hours after the call and archived on the website for 90 days.
-
-
You’re invited! Join CEO, Rick Stewart, this morning for a virtual presentation at the Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference. When: Tuesday, February 11, at 10am ET? Where: bit.ly/Achieve-webcast? ? If you are interested in learning more about our ambition to help people struggling with nicotine dependence, please visit AchieveLifeSciences.com.??
-
-
We are pleased to announce that the Data Safety Monitoring Committee (DSMC) has successfully completed its second independent review of the ORCA-OL trial. The DSMC has confirmed that no new safety concerns were identified, and the trial may proceed as planned. ? ? As Dr. Cindy Jacobs, President and CMO of Achieve Life Sciences, puts it: “The positive outcome of the DSMC’s second review continues to confirm the previous findings from our Phase 2 and Phase 3 trials regarding the overall safety profile.”? ? We are excited about the potential to tackle one of the world’s most pressing public health challenges: helping millions of people quit smoking and vaping.? ? Learn more: bit.ly/ORCA-DSMC
-
-
Achieve is thrilled to announce two additions to our Board of Directors: Dr. Kristen Slaoui and Nancy Phelan. Kristen B. Slaoui, Ph.D., is the Chief Corporate Development Officer at Galderma and spent 20 years at GSK contributing to groundbreaking pulmonary disease research. Nancy R. Phelan leads Customer Engagement solutions at Trinity Life Sciences and brings over 25 years of executive leadership in the biopharma and service industries. Join us in welcoming them to the team! Learn more: bit.ly/BOD-announcement
-
-
Our ongoing ORCA-OL clinical trial has officially reached the long-term exposure requirement for NDA submission, which remains on track for the second quarter of 2025. The ORCA-OL clinical trial continues to evaluate longer-term safety exposure of the dosing regimen in individuals who want to end their nicotine dependence. Learn more: bit.ly/ORCA-OL
-
Join the Achieve Life Sciences team next week in San Francisco at the JPM Healthcare Conference! Our team will be onsite to share the latest innovation in smoking cessation research and how we hope to transform the treatment landscape for nicotine dependence. Looking forward to connecting with you at the event and discussing how we can help shape a healthier, nicotine-free future.
-
-
The countdown to 2025 is on! Now is the perfect time to encourage your patients to start the year with healthy resolutions and embrace a smoke-free future.? ? #SmokingCessation #QuitSmoking #Nicotine #Smokers #NewYearsResolution?
-
Achieve Life Sciences wishes you and your loved ones a wonderful holiday season! As we reflect on the year, we’re proud of the progress made in the fight against nicotine dependence and remain committed to supporting a smoke-free future for all.?? ? #SmokingCessation #QuitSmoking #Nicotine #Smokers?
-
-
As we approach the end of the year, we're taking a moment to reflect on some of our key milestones and achievements:? - The FDA granted Breakthrough Therapy Designation for cytisinicline in the treatment of e-cigarette and vaping nicotine dependence? - Our positive Phase 2 ORCA-V1 study results were published in JAMA Internal Medicine? - We successfully completed enrollment in the ORCA-OL Clinical Trial, evaluating the long-term effects of our novel 3mg cytisinicline dosing regimen in individuals who smoke or vape nicotine? ? Visit our website to learn more about our ongoing research: https://lnkd.in/dMDU2K2? ? #SmokingCessation #QuitSmoking #Nicotine #Smokers?
-